Search clinical trials for: Pulmozyme (dornase alfa)

Total 3093 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Cancer | Anemia

United States
Janssen-Ortho Inc., Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Carcinoma | Prostate
Amgen

Completed

Heart Failure and Anemia

Heart Failure | Anemia
Amgen

Completed

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

Lymphoma | Breast Neoplasms | Lung Neoplasms | Multiple Myeloma | Chronic Lymphocytic Leukemia
Amgen

Completed

Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease

Anemia | Kidney Disease
Akebia Therapeutics

Completed

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Anemia Associated With Chronic Kidney Disease

United States
Sandoz
Hexal AG

Completed

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v. (EPO-PASS)

Chronic Kidney Disease

Poland, Germany, Romania, Italy, Austria, Bulgaria, France, Macedonia, The Former Yugoslav Republic of, Russian Federation, Ukraine
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Hepatitis B

China
Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Cervical Cancer | Ovarian Cancer

China
Westfälische Wilhelms-Universität Münster
Chiesi GmbH

Recruiting

German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa (GoPEG)

Fabry Disease

Germany
Taipei Veterans General Hospital, Taiwan

Not yet recruiting

Higher Dose of Alglucosidase Alpha for Pompe Disease

Glycogen Storage Disease Type II
The University of Hong Kong
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Nasopharyngeal Carcinoma | Metastatic Cancer | Recurrent Carcinoma | Non-keratinizing Carinoma

Hong Kong
Amgen

Completed

Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants

Inflammatory Diseases

United Kingdom
University of Turin, Italy

Completed

Prospective Randomized Trial Comparing Corifollitropin-alfa Late Start vs. Corifollitropin-alfa Standard Start in Expected Poor, Normal and High-responders Undergoing IVF

Fertility Disorders

Italy
Organon and Co

Completed

A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788) (Realize)

In Vitro Fertilization
The Hospital for Sick Children

Completed

Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure

Kidney Failure, Chronic

Canada
Janssen-Cilag B.V.

Completed

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients

Anemia | HIV
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Stomach Neoplasms | Rectal Neoplasms
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.

Anemia | Blood Transfusion | Orthopedic Procedures
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery

Blood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Cardiovascular Surgical Procedure | Blood Transfusion, Autologous
Janssen-Ortho Inc., Canada

Completed

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery

Anemia
Janssen Cilag S.A.S.

Terminated

Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency

Anemia | Renal Failure, Chronic Renal Failure
Janssen Pharmaceutica N.V., Belgium

Completed

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

Chronic Renal Failure
Amgen

Completed

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

Chronic Kidney Disease
Amgen

Completed

A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy

Anemia
AM-Pharma

Completed

Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia

Hypophosphatasia

Germany
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Extension Study of PRX-102 for up to 60 Months

Fabry Disease

United States, Spain, United Kingdom, Paraguay
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Lymphoma | Leukemia | Breast Cancer | Chronic Myeloproliferative Disorders | Anemia | Small Intestine Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Amgen

Completed

Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

Cancer | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
Kyowa Kirin Co., Ltd.

Completed

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Anemia

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Anemia

United States
Amgen

Completed

Fixed Dose NESP Study in Subjects With CRI

Pre-Dialysis
Amgen

Completed

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Anemia
Amgen

Completed

Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects

Anemia
Hoffmann-La Roche

Completed

PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

United States, Puerto Rico
Sanofi

Recruiting

Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France (OPERA)

Acid Sphingomyelinase Deficiency (ASMD)

France
Queen Mary University of London

Not yet recruiting

Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder (PEBBLE)

Transitional Cell Carcinoma | Bladder Cancer
GlaxoSmithKline
Merck KGaA, Darmstadt, Germany

Terminated

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Neoplasms

Spain, United States, France, Netherlands, Canada
Universitair Ziekenhuis Brussel

Completed

D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists

Infertility

Belgium
Genzyme, a Sanofi Company

Completed

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

Glycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease

United States
Protalix
Chiesi Farmaceutici S.p.A.

Completed

Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

Fabry Disease

Australia, Netherlands, United Kingdom, Canada, Czechia, Norway, Slovenia
GlaxoSmithKline
Quintiles, Inc.; ERT: Clinical Trial Technology Solutions; Q2 Solutions; HemoCue

Completed

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

Anaemia

United States
ISU Abxis Co., Ltd.
Catalyst Biosciences

Completed

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Hemophilia B

Korea, Republic of

3

Subscribe